Ophthalmic Goods · SIC 3851

Bausch & Lomb Corp

BLCO

Watch

Latest revenue

$1.24B

as of 2026-03-31

Latest net income

$-71.0M

as of 2026-03-31

Net margin

-5.7%

as of 2026-03-31

Community sentiment

Where do you think BLCO is heading?

1 month
6 months
12 months
5 years
Sign in free to vote and see community sentiment

Keep private notes on BLCO — thesis, target price, catalysts to watch.

Visible only to you. Never shared. Never used to train AI.

Sign in to add your own notes

BLCO vs S&P 500 · rebased to 100

-6.1% / yr 25.8 pts / yr vs S&P 500(S&P 500 +19.7% / yr) 22.7% total
Compare:

Market data

Price feed temporarily unavailable for BLCO.

What this company does

AI

Item 1. Business Bausch + Lomb Corporation (and its subsidiaries) (“Bausch + Lomb,” “we,” “us,” “our” or the “Company”) is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Our mission is simple, yet powerful: helping you see better, to live better. Founded in 1853, Bausch + Lomb has a significant global research, development, manufacturing and commercial footprint of approximately 13,000 employees and a presence in approximately 100 countries. As a fully integrated eye health business, Bausch + Lomb has a comprehensive portfolio of approximately 400 products, which includes an established…

AI summary unavailable — showing raw filing excerpt

Generated from BLCO's filing dated 2026-02-18

Key risks

AI

Item 1A. Risk Factors Our business, financial condition, cash flows and results of operations are subject to various risks and uncertainties. You should carefully consider the risks and uncertainties described below, together with all of the other information in this Form 10-K, including those risks set forth under the heading entitled “Forward-Looking Statements” and in other documents that we file with the SEC and the CSA, before making any investment decision with respect to our common shares or debt securities. If any of the risks or uncertainties actually occur or develop, our business, financial condition, cash flows, results of operations and/or future growth prospects could change,…

AI summary unavailable — showing raw filing excerpt

Generated from BLCO's filing dated 2026-02-18

5.1
of 10

ActaClear Score

Neutral
#4 of 7 in Ophthalmic Goods
+0.4 · 5d
Profitability·25%
5.0
Growth·15%
3.3
Value·20%
3.3
Quality·20%
Momentum·20%
8.3

Computed from 5 years of SEC fundamentals + latest market data, ranked within Ophthalmic Goods (7 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.